¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inhibition coefficient"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • migration inhibition factor
    À̵¿ÀúÁöÀÎÀÚ
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • noncompetitive inhibition
    ºñ°æÀï¾ïÁ¦
  • postsynaptic inhibition
    ½Ã³À½ºÀÌÈľïÁ¦, ¿¬Á¢ÀÌÈľïÁ¦
  • presynaptic inhibition
    ½Ã³À½ºÀÌÀü¾ïÁ¦, ¿¬Á¢ÀÌÀü¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý, »ó¹Ý¾ïÁ¦Á¤½Å¿ä¹ý
  • recurrent inhibition
    ȸ±Í¾ïÁ¦
  • retroactive inhibition
    ¿ªÇà±â¾ï¾ïÁ¦, ¾Õ±â¾ï¾ïÁ¦
  • reversible inhibition
    °¡¿ª¾ïÁ¦
  • selective inhibition
    ¼±ÅþïÁ¦
  • apparent diffusion coefficient
    °Ñº¸±âÈ®»ê°è¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ, ÀúÁö¹ÝÀÀ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • inhibition zone
    ¾ïÁ¦¿µ¿ª
  • irreversible inhibition
    ºÒ°¡¿ªÀúÁö
  • noncompetitive inhibition
    ºñ°æÀï¾ïÁ¦
  • postsynaptic inhibition
    ¿¬Á¢ÈľïÁ¦, ½Ã³À½ºÈľïÁ¦
  • presynaptic inhibition
    ¿¬Á¢Àü¾ïÁ¦, ½Ã³À½ºÀü¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • recurrent inhibition
    ȸ±Í¾ïÁ¦
  • reflex inhibition ileus
    ¹Ý»ç¾ïÁ¦Ã¢ÀÚ¸·ÈûÁõ
  • retroactive inhibition
    ¿ªÇà±â¾ï¾ïÁ¦, ¾Õ±â¾ï¾ïÁ¦
  • reversible inhibition
    °¡¿ª¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • HIT= hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • Internal inhibition
    ³»ºÎ¾ïÁ¦(Үݻåäð¤)
  • Lateral inhibition
    ÃøºÎ¾ïÁ¦(ö°Ý»åäð¤)
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coefficient of expansion
    ÆØÃ¢°è¼ö(̰̤ Ë­Ëà).
  • coefficient of extinction
    Èí¼ö°è¼ö(Ì·ËàË­Ëà), Èí±¤°è¼ö(Ì·Ë´Ë­Ëà).
  • coefficient of fecundity
    ¼öÁ¤·ü(áôïñëÒ).
  • coefficient of friction
    ¸¶Âû°è¼ö(ËÎ̤˭Ëà).
  • coefficient of oxygen utilization
    »ê¼ÒÀÌ¿ë °è¼ö.
  • coefficient of variability
    º¯À̰è¼ö, º¯µ¿ °è¼ö.
  • coefficient of variation
  • coefficient, phenol
    Æä³îÁö¼ö
  • coefficient, sedimentation
    ħ°­Áö¼ö
  • correlation coefficient
    »ó°ü°è¼ö(ßÓμÌõâ¦)
  • correlation coefficient
    »ó°ü°è¼ö(Ë×Ë´Ë­Ëà).
  • correlation coefficient
    »ó°ü °è¼ö
  • diffusion coefficient
    È®»ê °è¼ö
  • diffusion coefficient
    È®»ê°è¼ö (¡­Ìõâ¦).
  • distribution coefficient
    ºÐÆ÷°è¼ö, ºÐ¹è°è¼ö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition
    "(Àû,îå)Ç÷±¸(úìϹ) ÀÀÁý ÀúÇØ(ëêó¢îÁúª)"
  • hyperbolic inhibition
    ½Ö°î¼± ÀúÇØ(äªÍØàÊîÁúª)
  • immunological inhibition
    ¸é¿ª ÀúÇØ(Øóæ¹îÁúª)
  • inhibition
    ÀúÇØ(îÁúª)
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • inhibition constant
    ÀúÇØ»ó¼ö(îÁúªßÈâ¦)
  • inhibition index
    ÀúÇØÁö¼ö(îÁúªò¦â¦)
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
  • inhibition zone
    ÀúÇØ¿ª(îÁúªæ´)
  • linear inhibition
    ¼±ÇüÀúÇØ(àÊû¡îÁúª)
  • lysis inhibition
    ¿ëÇØÀúÇØ(éÁú°îÁúª)
  • macrophage inhibition factor
    ´ë½Ä¼¼Æ÷ÀúÇØÀÎÀÚ(ÓÞãÝá¬øàîÁúªì×í­)
  • migration inhibition factor
    À̵¿ÀúÇØ ÀÎÀÚ(ì¹ÔÑîÁúªì×í­)
  • mixed inhibition
    È¥ÇÕÀúÇØ(ûèùêîÁúª)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
AC abdominal circumference; abdominal compression; absorption coefficient; abuse case; acetate; acetylc...
ADC adult day care [facility]; affective disorders clinic; Aid to [Families with] Dependent Children; AI...
'Greek letter alpha' angular acceleration; first [carbon atom next to the carbon atom bearing the active group in organic...
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CV coefficient variation
% CV coefficient of variance
CC Correlation coefficient
Ds diffusion coefficient
DC Distensibility coefficient
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • myelinated afferent inhibition
    À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
  • negative feedback inhibition
    À½¼º µÇ¸ÔÀ̱⠾ïÁ¦
  • noncompetitive inhibition
    ºñ°æÇÕÀû ÀúÇØ
  • postsynaptic inhibition
    ½Ã³³½º ÈÄ ¾ïÁ¦
  • segmented inhibition
    ºÐÀýµÈ ¹æÇØ
  • self inhibition
    Àڱ⠾ïÁ¦
  • tonic inhibition
    ±äÀ强 ¾ïÁ¦
  • active coefficient
    Ȱ¼ºµµ °è¼ö
    ¹°ÁúÀÇ ³óµµ°¡ ³·À» ¶§¿¡ ¹ÝÀÀ·ÂÀº ³óµµ¿¡ ºñ·ÊÇϴµ¥ ³óµµ°¡ ³ô¾ÆÁ³À» ¶§´Â ¹ÝÀÀ·ÂÀÌ °¨¼ÒµÇ°í, ³óµµ¿¡ Ȱµ¿°è¼ö¸¦ °öÇÑ °Í¿¡ ºñ·ÊÇØ¼­ ¹ÝÀÀ·ÂÀÌ ³ªÅ¸³­´Ù.
  • apparent diffusion coefficient
    °Ñº¸±â È®»ê °è¼ö
  • attenuation coefficient
    °¨¼è °è¼ö
    ¾î¶² ƯÁ¤ÇÑ ¹°ÁúÀ» Åë°úÇÔÀ¸·Î½á ·¹ÀÌÀú ±¤¼ÓÀÇ Æò±ÕÃâ·ÂÀÇ »ó½Ç ȤÀº °¨¼ÒÀÇ ºñÀ².
  • capacity coefficient
    ¿ë·® °è¼ö
  • coefficient
    °è¼ö, À²
    1. ¾î¶² ÀÎÀÚÀÇ º¯µ¿À¸·Î ÃÊ·¡µÇ´Â º¯È­³ª È¿°úÀÇ Ç¥Çö. ¶Ç´Â µÎ °³ÀÇ ´Ù¸¥ ¾çÀÇ ¹èÀ²ÀÇ Ç¥Çö. 2. È­Çп¡¼­´Â È­ÇнÄÀÇ ¾Õ¿¡¼­ ±× È­ÇнÄÀÇ ¹èÀ²À» °¡¸®Å°´Â ¼ýÀÚ.
  • coefficient of correlation
    »ó°ü °è¼ö
    Á¦°öÇÏ¸é µÎ °³ÀÇ ¹«ÀÛÀ§ º¯¼öÄ¡ °£¿¡ »ó°ü Á¤µµ¸¦ ³ªÅ¸³»´Â Åë°è ¼ö´Ü. ´ëºÎºÐÀÇ »ó°ü °è¼ö°¡ Ç¥ÁØÈ­µÇ¾î +1
  • coefficient of displacement
    º¯À§ °è¼ö
  • coefficient of expansion
    ÆØÃ¢ °è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
contact inhibition of movement Reaction in which the direction of motion of a cell is altered following collision with another cell. In heterologous contacts both cell may respond (mutual inhibition) or only one (nonreciprocal). Type I contact inhibition involves paralysis of the locomotory machinery, Type II is a consequence of adhesive preference for the substratum rather than the dorsal surface of the other cell.
(18 Nov 1997)
contact inhibition of phagocytosis Phenomenon described in sheets of kidney epithelial cells that, when confluent, lose their weak phagocytic activity, probably because of a failure of adhesion of particles to the dorsal surface in the absence of ruffles.
(18 Nov 1997)
haemagglutination inhibition A variation of the haemagglutination technique. Some viral antigens, when coated on erythrocytes, spontaneously cause agglutination in the absence of antibody. In these situations, the specific antigen-antibody reaction actually prevents the agglutination of reagent RBCs. Haemagglutination inhibition cannot differentiate between isotypes of specific antibodies (IgG, IgA or IgM) although positive haemagglutination inhibition analysis of specimens treated with Staphylococcus aureus Protein A (discussed above under coagglutination) to remove the IgG isotype antibodies has been used to imply the presence of specific IgM antibodies to the specific viral antigen. The crude quantitation of the specific antibodies is possible using serial dilution (titre).
(05 Mar 2000)
haemagglutination inhibition test <investigation> A clinical lab test used to detect the presence of a certain haemagglutinating virus or other haemagglutinin antigen based on whether the red blood cells in the sample lose the ability to clump together when the antibody to the virus or other antigen is added to it.
If the virus or antigen is present, the antibody kills it and thereby stops it from being able to stick the red blood cells to each other.
(09 Oct 1997)
haemagglutination inhibition tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of haemagglutination.
(12 Dec 1998)
potassium inhibition Arrest of the heart in the fully relaxed state as a result of potassium intoxication.
(05 Mar 2000)
haptenic inhibition <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
hapten inhibition of precipitation Inhibition of precipitation that occurs when the precipitin has combined with hapten of the same specificity as the subsequently added antigen.
(05 Mar 2000)
proactive inhibition The state or process hypothesised to account for poorer learning rate for elements later in a series as compared to the learning rate for elements coming earlier in a series.
(12 Dec 1998)
product inhibition Inhibition of an enzyme activity by a product of the reaction catalyzed by that enzyme.
(05 Mar 2000)
selective inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
noncompetitive inhibition <chemistry> A form of enzyme inhibition which cannot be reversed by increasing the amount of substrate in the reaction.
(09 Oct 1997)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
nonreciprocal contact inhibition <cell biology> Collision behaviour between different cell types in which one cell shows contact inhibition of locomotion and the other does not. An example is the interaction between sarcoma cells and fibroblasts (the former not being inhibited).
(18 Nov 1997)
density dependent inhibition of growth <cell culture> The phenomenon exhibited by most normal (anchorage dependent) animal cells in culture that stop dividing once a critical cell density is reached.
The critical density is considerably higher for most cells than the density at which a monolayer is formed, for this reason, most cell behaviourists prefer the term density dependent inhibition of growth as this avoids any confusion with contact inhibition of locomotion, a totally different phenomenon that is contact dependent.
(12 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á